Overall, the PFS was 2.8 months for PD-1/PD-L1 naïve urothelial and renal cancer, 5.2 months for PD-1/PD-L1 resistant patients, and 3.5 months for prostate cancer patients [150]. Here, CD274 is linked to prostate carcinoma.